How can we implement current therapies and interventions to achieve glycemic control?

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by impaired insulin secretion and increased insulin resistance.
• The natural history of T2DM involves a gradual decline in beta-cell function and the emergence of multiple pathophysiological defects, including glucose toxicity, lipid toxicity, and impaired insulin response.
• Conventional treatment approaches often fall short due to their inability to address the multifaceted and evolving nature of T2DM.

Purpose of the Study:

• To review the stages of T2DM progression.
• To evaluate the limitations of monotherapy in managing T2DM.
• To discuss the role of combination oral therapies in achieving and sustaining glycemic control.

Main Methods:

• Review of the pathophysiology and progression of T2DM.
• Analysis of treatment algorithms and therapeutic limitations.
• Evaluation of evidence supporting combination oral therapy in T2DM management.

Main Results:

• T2DM progresses through distinct stages, with beta-cell function deteriorating over time.
• Factors like insulin resistance, glucose toxicity, and impaired insulin secretion contribute to disease progression.
• Combination oral therapy offers a safe and effective strategy to manage hyperglycemia and associated risk factors in T2DM.

Conclusions:

• The primary goal in T2DM management is to normalize physiological function as closely as possible.
• Achieving optimal glycemic control necessitates addressing multiple underlying defects.
• Combination oral antihyperglycemic agents are essential for comprehensive T2DM treatment, targeting various pathophysiological pathways.